RAR M Arana-Trejo

R M Arana-Trejo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


R M Arana-Trejo has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chromosomal imbalances in four new uterine cervix carcinoma derived cell lines

    by Alfredo Hidalgo, Alberto Monroy, Rosa Ma Arana, Lucía Taja, Guelaguetza Vázquez, Mauricio Salcedo


  • BCR/ABLp210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML)

    by R.M. Arana-Trejo, E. Ruíz Sánchez, G. Ignacio-Ibarra, E. Báez De La Fuente, O. Garces, E. Gómez Morales, M. Castro Granados, R. Ovilla Martínez, M.E. Rubio-Borja, L. Solís Anaya, et al.

    There are two major forms of the BCR/ABL fusion gene, involving ABL exon 2, but including different exons of BCR gene. The transcripts b2a2 or b3a2 code for a p210 protein. Another fusion gene leads ...


    • 1 May 1997
      • Vol. 49  (3) , 209-14

    [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].

    by R M Arana-Trejo, R Ovilla-Martínez, E Gómez-Morales, L Meillon-García, A Cervantes-Peredo, J González-Llaven, J Pizzuto-Chávez, S Kofman-Alfaro

    To evaluate if human recombinant interferon alpha (IFN) combined with chemotherapy is able to suppress the Philadelphia chromosome clone in patients with chronic myeloid leukemia (CML). The cytogenetic evolution in 53 patients with CML in chronic phase de novo was studied. They received one of three treatment schemes: a) induction of remission with daunorubicin, vincristine, cytosine arabinose and prednisone (DOAP) and maintenance with IFN (n = 12); b) induction with busulfan (BUS) or hydroxyurea (HYDX) and maintenance with IFN (n = 26); c) induction with DOAP and maintenance with BUS (n = 15). The remission was seen two to six months after the start of treatment: 10 had complete remission, six a partial one, 14 a minor remission and 23 none. The 16 with complete or partial response received treatment with IFN. None of the 15 cases maintained with BUS had complete or partial response. The proportion of cases with complete response (3/12) was slightly lower in patients treated with intensive chemotherapy (BUS/HIDX/IFN) than in those receiving conventional treatment (7/26). Our results showed that: a) IFN in combination with chemotherapy induced partial or complete response in 30% of our cases; and b) intensive chemotherapy combined with IFN was not superior in terms of a cytogenetic response to treatment with monodrugs (BUS/HIDX) and IFN.

    • 1 January 1997
      • Vol. 28  (2) , 209-14

    Cytogenetic findings in 303 Mexican patients with de novo acute myeloblastic leukemia.

    by R M Arana-Trejo, E Gómez-Morales, M E Rubio-Borja, J J Kassack-Ipiña, A Cervantes-Peredo, S Guerrero-Rivera, J González-Llaven, M Gutiérrez-Romero, J Pizzuto-Chávez, S Kofman-Alfaro

    In this report we show the chromosomal changes seen in a group of 303 Mexican patients with de novo Acute Myeloblastic Leukemia (AML). Two hundred forty-two patients were diagnosed and treated at two hospitals affiliated with the Instituto Mexicano del Seguro Social (IMSS). These are the Centro Medico Nacional Siglo XXI and Centro Medico La Raza Hospitals; the remaining 61 patients were diagnosed and treated at the Hospital General de Mexico (HGM). Clonal abnormalities were detected in 75.6% of the patients; this result agrees with what has been reported in other large series of AML studies. The incidence of changes per hospital was similar in patients from the IMSS hospitals (72-75%), while an increase was seen in patients from the HGM (85.2%). The chromosomal changes seen in this study in order of frequency were: t(15;17)[18.8%], t(9;22)[9.2%], miscellaneous chromosomal changes (mainly rearrangements of chromosomes 1,2,3,12y17)[8.2%], abnormalities of 16q22 [7.3%], t(8;21)[6.3%], -7/del(7q)[5.6%], t(6;9)[5.3%], and abnormalities of 11q23 [4.6%]. We reported an increase in the incidence of certain types of chromosomal changes seen in cases of AML, in comparison with reports from other countries. These differences could be due to methodological variations, although ethnic, socioeconomic and nutritional differences must not be disregarded. We support this finding when comparing distribution of changes in the population of patients seen in the IMSS hospitals with those from the HGM; the main difference lies in the socioeconomic level.